860-837-2048 (t) | travis.hinson@jax.org 19 20 Thick filament sarcomere mutations are the most common cause of hypertrophic cardiomyopathy (HCM), 21 a disorder of heart muscle thickening associated with sudden cardiac death and heart failure, with unclear 22 mechanisms. We engineered an isogenic panel of four human HCM induced pluripotent stem cell (iPSc) 23 models using CRISPR/Cas9, and studied iPSc-derived cardiomyocytes (iCMs) in 3-dimensional cardiac 24 microtissue (CMT) assays that resemble in vivo cardiac architecture and biomechanics. HCM mutations 25 result in hypercontractility in association with prolonged relaxation kinetics in proportion to mutation 26 pathogenicity but not calcium dysregulation. RNA sequencing and protein expression studies identified 27 that HCM mutations result in p53 activation secondary to increased oxidative stress, which results in 28 increased cytotoxicity that can be reversed by p53 genetic ablation. Our findings implicate 29 hypercontractility as an early consequence of thick filament mutations, and the p53 pathway as a 30 molecular marker and candidate therapeutic target for thick filament HCM. 31 32 35 hypertrophy (LVH) with preserved systolic contractile function 2 . In young athletes, HCM manifests as a 36 common cause of sudden cardiac death; while in adults, HCM is associated with heart failure that may 37 progress to require cardiac transplantation 3 . Over the last few decades, the genetic basis of HCM has been 38 demonstrated by inheritance of autosomal dominant mutations in components of the force-producing 39 sarcomere 4 . About two-thirds of HCM patients harbor heterozygous mutations in one of two sarcomere 40 genes: b-myosin heavy chain (MHC-b is encoded by MYH7) or myosin-binding protein C (MYBPC3) 4 . 41 Along with titin, MHC-b and MYBPC3 are located in the thick filament where ATP hydrolysis by MHC-42
Introduction
Hypertrophic cardiomyopathy (HCM) is a human disorder that affects 1 in 500 individuals with uncertain 34 mechanisms 1 . Patients with HCM are diagnosed by the presence of unexplained left ventricular cardiomyocyte assays have supported both gain-and loss-of-force production models of HCM 48 pathogenesis, thus suggesting that changes in force production may not be a shared consequence of HCM 49 mutations. For example, MYH7-R453C (arginine 453 substituted with cysteine) increased while MYH7-50 R403Q (arginine 403 substituted with glutamine) decreased force production in reconstituted actomyosin HCM iPSc models have not been comprehensively studied. 6 The apparent difficulty in establishing the pathogenesis of HCM has been attributed in part to: 1) 7 multiprotein assembly limitations that hinder sarcomere analysis, 2) mouse models that express distinct 8 sarcomere components compared to humans (e.g. MYH6 instead of MYH7), 3) the lack of isogenic iPSc-9 derived cardiomyocyte cell lines to control for genetic and epigenetic variation and 4) the absence of 10 biomimetic 3-dimensional (3d) human cardiac tissue functional assays. Here, we set out to address these 11 limitations by combining genetic engineering tools to generate a series of scarless MYH7 and MYBPC3 12 HCM mutations in human isogenic iPScs that are differentiated to cardiomyocytes (iCMs) that express 13 human sarcomere contractile components. We generated 3d cardiac microtissues (CMTs; fig.1B ) to 14 identify mechanical consequences of HCM mutations in combination with molecular assays to interrogate 15 insights into HCM pathogenesis. 16 17 Results 18 Generation of HCM iPSc and CMT models using CRISPR/Cas9 19 We began by identifying two HCM mutations in MYH7, R403Q and V606M (valine 606 substituted with 20 methionine), which cause autosomal dominant HCM in both humans 9, 12 and mice 13, 14 . Both mutations are 21 located in subfragment 1 (S1) of MHC-b near the actin-interacting domain ( fig.1A ), but R403Q leads to a 22 more severe cardiomyopathy compared to V606M 14 . Because MHC-b physically interacts with 23 MYBPC3 4 , we hypothesized that these mutations could lead to HCM by a shared mechanism. 24 We next selected a common pathogenic truncation mutation in MYBPC3 (clinvar.com), a guanine 25 insertion that leads to tryptophan 792 substituted with valine followed by a frameshift (Trp792ValfsX41; 26 MYBPC3 +/-), and a common pathogenic missense mutation, arginine 502 substituted with tryptophan 27 (R502W) that is found in up to 2.4% of HCM patients ( fig.1A ) 15 . We generated scarless, isogenic iPSc 28 models of these four mutations with CRISPR (clustered regularly interspaced short palindromic repeats) 29 technology using delivery of a single optimized guide RNA, Cas9 nuclease and a single-stranded 30 oligodeoxynucleotide (ssODN) repair template ( fig.1B , table S1). We chose an isogenic approach to focus 31 our investigation on the direct functional consequences of the four thick filament mutations, while 32 controlling for background epigenetic and genetic variation. To generate the four iPSc models, we 33 screened 1,111 clones by Sanger sequencing (table S1). After screening for off-target genome editing loci 34 by sequencing (crispr.mit.edu) and karyotype abnormalities by virtual karyotyping using arrays, we 35 directly differentiated iPScs 16 followed by metabolic enrichment 17 to generate purified iCMs. Finally, we 36 combined iCMs with tissue-forming fibroblasts and an extracellular matrix slurry to generate a 3d CMT 37 assay that recapitulates native cardiac architecture and mechanics, which has been adapted from prior 38 assays applied to study contractility phenotypes of dilated and PRKAG2 cardiomyopathy iPSc models 18-39 20 . 40 41 Four thick filament HCM mutations result in hypercontractility in CMT assays 42 To study the mechanical consequences of MYH7 and MYBPC3 mutations in a biomimetic context, we 43 optimized our previously studied CMT assay 18, 20 to increase sarcomere gene expression of thick filament 44 transcripts. In particular, MYH7:MYH6 is upregulated in the developing human heart 21 and iCMs express 45 fetal to neonatal stage transcript levels. By increasing the size of the microfabricated tissue gauges 46 (µTUG) including a proportional increase in cantilever dimensions and spring constant ( fig.S1A ), we improved CMT durability from four days to ten days ( fig.S1B ), which was associated with a 42% 48 increase in MYH7:MYH6 expression ( fig.S1C , left panel) and 630% increase in cardiac troponin I 49 (TNNI3) expression ( fig.S1C, right panel) . For all CMT studies, we measured contractility parameters on 50 day seven after tissue compaction has completed and force production has plateaued (fig.S1D). 51 1 compared to 21.7 µN in isogenic controls ( fig.1C ). We then tested whether the increased twitch force 2 generated by R403Q +/was secondary to changes in sarcomere isoform expression or clonal variation. 3 TNNI3 expression 22 , a transcript marker that is related to cardiomyocyte maturation, was unchanged 4 ( fig.S2A , B) 22 . Increased contraction force was also similar between two independent R403Q +/clones 5 ( fig.S2C ). Moreover, CMT cross-sectional area did not differ between HCM mutations and isogenic 6 controls ( fig.S2D ). We next tested whether CMT assays could predict pathogenicity of MYH7 mutations 7 by testing CMTs generated from iCMs with the less pathogenic MYH7 variant V606M +/-, which is also 8 located in the actin-binding domain of S1 ( fig.S1F ). V606M +/-CMTs generated 31.9 µN twitch force 9 compared to 21.7 µN in isogenic controls ( fig.1C ), which was less than R403Q +/-. We conclude that 10 MYH7 variant pathogenicity positively correlates with maximum contraction force in CMT assays. We 11 also generated two MYBPC3 mutant CMT models to compare to MYH7 models. MYBPC3 +/and 12 MYBPC3-R502W +/-CMTs generated 41.0 µN and 42.9 µN twitch force compared to 21.7 µN in isogenic 13 controls, respectively ( fig.1D ). Because sarcomere function also contributes to twitch-independent 14 contraction force, or resting tension, we measured this parameter in CMTs. In parallel to twitch force 15 changes, resting tension was increased in all HCM models except for MYH7-V606M +/-( fig.1E ). Because 16 V606M +/results in a mild phenotype, we did not further characterize this variant. 17 To characterize the basis of hypercontractility, we measured calcium handling in CMTs by 18 optical imaging and calcium-dependent fluorescent dyes. Surprisingly, HCM-associated 19 hypercontractility did not appear to be related to changes in calcium delivery to the myofilament as 20 calcium transients were unaffected in all HCM mutations tested ( fig.1F , G). This is distinct from CMT 21 treatment with verapamil, a voltage-gated calcium channel blocker, which resulted in diminished CMT 22 calcium transients as expected ( fig.1H ). Because the increase in resting tension could be secondary to 23 myofilament activation in the setting of increased resting calcium levels, we stained iCMs with Indo-1 24 and measured both resting and caffeine-induced activation. Indo-1 signal was unchanged ( fig.S2E, F) . 25 Finally, we tested CMT myofilament calcium sensitivity by varying the extracellular calcium 26 concentration from 1 mM to 3 mM and quantified CMT function. We found that at both low and high 27 calcium, HCM CMTs resulted in hypercontractility ( fig.1I ). These data support a model whereby thick 28 filament HCM mutations result in a state of hypercontractility that is independent of changes in calcium 29 handling. 30 We also measured HCM-associated contraction and relaxation kinetics by quantifying maximum 31 contraction velocity, contraction time and relaxation half-time across all HCM mutations. Compared to 32 controls, HCM CMTs exhibited a 79-121% increased maximum contraction velocity ( fig.2A further supports that impaired relaxation is a consequence of HCM thick filament mutations, which has 35 also been documented in HCM patients 23 . These kinetic changes are distinct from kinetic changes induced 36 by omecamtiv mecarbil 24 , a direct myosin activator that prolongs contraction time.
38
Reduction of hypercontractility by calcium channel blockers and direct myosin inhibitors 39 We generated CMTs from the severe HCM mutation MYH7-R403Q +/-, and assessed changes in twitch 40 force and resting tension after treatment with two candidate small molecules. We started by evaluating 41 one of the most commonly prescribed therapies for HCM patients, the voltage-dependent calcium channel 42 blocker verapamil 25, 26 . In accord with changes in calcium transients ( fig.1H ), the addition of verapamil 43 reduced twitch tension by 31.7% in R403Q +/-CMTs ( fig.3A ). We also tested the direct myosin inhibitor 44 blebbistatin to assess whether myosin inhibitors may similarly reduce HCM-associated hypercontractility 45 in R403Q +/-CMTs. Since blebbistatin binds to MHC-b distinct from residues near R403Q, and does not 46 interfere with actin-binding or actomyosin disassociation 27 , we hypothesized that this molecule may also reduce twitch force. Similar to verapamil, blebbistatin similarly reduced twitch force by 35.3% ( fig.3B ). 48 Because blebbistatin inhibits myosin by a calcium-independent mechanism and resting calcium levels 49 were not altered by HCM mutations, we hypothesized that only blebbistatin could normalize both twitch 50 and resting tension induced by HCM mutations. Indeed, blebbistatin but not verapamil reduced resting 1 tension by 10.2% ( fig.3C ). These data obtained from R403Q +/-CMTs suggest that therapeutic agents that 2 reduce both twitch and resting forces may be more efficacious for HCM patients, which may explain why 3 verapamil has been observed to have limited clinical efficacy in some HCM patients 28 . 4 5 MYH7-R403Q +/-CMTs exhibit myofibrillar disarray and iCM hypertrophy 6 To determine whether HCM mutations affect sarcomere structure in CMTs, we fixed CMTs and stained 7 sarcomeres using antibodies to Z-disc protein alpha actinin with DAPI co-stain ( fig.4A ). We again 8 focused on R403Q +/because this mutation is highly pathogenic in humans and in our mechanical assays. To better define the HCM-associated gene transcript program, we analyzed differentially-42 expressed transcripts that were common to all HCM iCM models ( fig.S4C and table S3 ). In accord with 43 the close proximity of HCM samples by PCA analysis, differentially-expressed transcripts were also 44 highly shared among HCM models. Of 1050 total upregulated transcripts, 320 were shared by at least two 45 HCM models, and of the 1177 total downregulated transcripts, 419 were shared by at least two HCM 46 models. Of note, the HCM phenotype did not correlate with expression of cardiac chamber-specific 47 markers such as myosin light chain 7 (MYL7), myosin light chain 2 (MYL2) and potassium channel HCN4 overlap. In parallel to transcript levels, p53 and p21 protein levels were increased in HCM iCM lysates 1 (fig.5G-I). In addition, fixed and immunostained HCM CMTs also exhibited increased p53 staining 2 within the nuclei of ACTN2+ iCMs ( fig.5J , K). Unexpectedly, these results implicate altered p53 3 signaling as a common molecular consequence of thick filament HCM mutations. 4 5 HCM iCMs exhibit increased cytotoxicity induced by metabolic stress that can be rescued by p53 6 inhibition. 7 To understand the role of elevated p53 signaling in HCM iCM models, we first determined whether p53 8 activation was related to increased iCM stress. In normal growth media, we observed no change in HCM 9 iCM cell death ( fig.S4E ), which was also consistent with our observation that CMT cell number and 10 tissue cross-sectional area were not changed by HCM mutations. We then considered whether HCM 11 iCMs were more susceptible to stress. Informed by the clinical observation that HCM patients have bio-12 energetic deficits in vivo 32 as well as the increased expression of mitochondrial gene transcripts in HCM 13 iCMs ( fig. 5E ), we measured iCM cytotoxicity induced by metabolic stress from glucose removal that has 14 been used by others to induce energy stress 33 . We found that HCM iCM models exhibited elevated To gain insights into linkages between thick filament HCM mutations and p53 activation, we 21 started by measuring known molecular activators of p53 including DNA damage 34 and oxidative stress 35 . 22 While the levels of phosphorylated histone 2A member X (H2A.X; fig.6E ), a marker of DNA damage 23 was not different between R403Q +/-iCMs compared to controls, reactive oxygen species (ROS) levels 24 were increased over three-fold ( fig.6F ). Because ROS generation is most commonly generated in 25 mitochondria, we also stained iCMs with MitoSOX ( fig.6G ) and MitoTracker dyes ( fig.6H ) to quantify 26 mitochondrial-derived ROS and mitochondrial content, respectively. Both of these assays showed 27 increased signal in HCM iCMs compared to controls. Based on these results, we conclude that HCM 28 mutations result in increased oxidative stress that results in a p53-dependent metabolic vulnerability to 29 energy stress.
31

Discussion
32
The genetic basis of HCM, most commonly due to thick filament sarcomere mutations, was identified 33 decades ago, yet the mechanisms that connect sarcomere gene mutations with the HCM phenotype still 34 remain unclear in part because of the lack of a robust human in vitro model system to interrogate 35 proximal mechanisms of HCM pathogenesis. Here, we engineered four human HCM models using 36 CRISPR to generate isogenic mutations in two of the most commonly mutated sarcomere genes, and 37 measured the mechanical consequences of these variants in a 3d CMT assay. This approach demonstrated 38 a convergent model of HCM pathogenesis whereby thick filament HCM mutations induce a state of 39 hypercontractility due to both increased twitch force and resting tension. The increased resting tension has 40 particular importance as this component of contraction force is not affected by therapeutics that target 41 only voltage-dependent factors such as the L-type calcium channel. 42 Our results of hypercontractility are in accord with recent functional studies of HCM-associated 43 thin filament mutant mouse models that support a sarcomere tension model 36 . Thin filament HCM 44 mutations were found to increase tension primarily by increasing myofilament calcium sensitivity as interactions that report changes in the accessibility of myosin heads to generate force in the setting of 49 HCM mutations 37 . Our inability to observe previously described alterations in calcium handling may be 50 due to the nature of the variants studied or due to non-cell-intrinsic mechanisms. We propose that calcium handling defects are likely indirect consequences of heart failure, but not directly due to thick filament 1 HCM mutations. In the future, it will be important to test other thick filament variants to identify potential 2 functional heterogeneity, as well as to compare to thin filament CMT phenotypes. 3 Our study also illustrates how HCM-associated hypercontractility is maladaptive due to 4 increased oxidative stress, which is associated with reduced viability in the setting of metabolic stress. 5 Energy imbalance in HCM patients with significant LVH has been identified in other studies 38 , but our 6 study is the first to implicate an early, cell-intrinsic metabolic vulnerability that results in altered cell 7 survival. While we did not observe an energy imbalance in HCM iCMs in unstressed conditions, this may 8 be secondary to the fetal nature of iCM metabolism that favors glucose rather than fatty acids for energy 9 production. 10 Finally, we identify that HCM-associated ROS production leads to activation of p53. While p53 11 has been well studied in the context of cancer and other disorders, it has not been implicated in HCM 12 pathogenesis to our knowledge, and only recently implicated in regulating the cardiac transcriptome 39 . 13 Notably, p53 genetic ablation also protected against heart failure due to pressure-overload, but promoted 14 age-associated cardiac dysfunction 39 . Our results suggest that p53 ablation would be beneficial in HCM, 15 and therefore molecular linkages between sarcomere variants, oxidative stress and p53 activation will 16 need to be addressed in future studies with potential therapeutic implications. Finally, our robust genome-17 engineered platform using isogenic human iPScs combined with CMT assays demonstrates a robust 18 approach to interrogate HCM pathogenesis, test cardiomyopathy therapeutics, as well as classify 19 sarcomere gene variants of unknown significance. 20 21
Methods
22
IPSc culture, iCM differentiation and enrichment 23 Parental human iPSc line used for all studies was PGP1, a normal control line obtained from Coriell 24 Institute (GM23338), and that has been described previously 18, 20 . This study was approved by the Jackson 25 Laboratory institutional review committee and IRB approval was obtained as part of the Personal Genome 26 Project. All iPSc lines were maintained on Matrigel (Corning)-coated tissue culture plates in mTeSR1 27 media (Stemcell). IPSc lines were screened for copy number variants using Illumina SNP arrays as 28 previously described 18 . IPScs were differentiated to iCMs by sequential targeting of the WNT pathway as 29 described previously 40 . ICMs were maintained in RPMI with B27 supplement (ThermoFisher) unless 30 otherwise noted. ICMs were enriched by metabolic selection by previously described methods 17 . On day 31 12 of iCM differentiation, beating iCMs were enriched by adding 4 mM DL-lactate (Sigma) in glucose-32 free DMEM media (ThermoFisher) for 48 hours. Following selection, enriched iCMs were maintained in 33 RPMI with B27 supplement. Only differentiation batches with >90% troponin T2+ cells by FACS or 34 estimated by morphology were considered to be high purity for further assays. For all assays, iCMs were 35 studied on differentiation day 30-35. For all iCM and CMT assays, at least biological triplicates 36 (differentiation batches) were studied. 37 CRISPR/Cas9 iPSc and iCM gene editing 38 Genetic modifications were generated using scarless iPSc clonal selection by following protocols 39 described previously 18 . For MYH7 and MYBPC3 mutation generation, PGP1 iPScs were electroporated 40 with pCAG-eGFP-2A-CAS9 plasmid (obtained from Addgene), a single-stranded mutation-specific 41 90mer oligonucleotide and an optimized guide RNA plasmid (table S2) . After 48 hours, GFP+ iPScs were 42 sorted by flow cytometry (FACS), clonally expanded and Sanger sequenced for genotyping. Guide RNAs 43 were designed and optimized using in silico methods that reduce risk of off-target mutations 44 (crispr.mit.edu). For MYH7 R403Q gene-editing, the corresponding region of MYH6 was sequenced to 45 verify no off-target MYH6 mutation. For lentiCRISPR (v2) experiments (Addgene), protocols for gRNA 46 cloning and lentivirus production was obtained from published methods and multiplicity of infection of 3 was used 41 .
48
CMT production and force measurements 49 CMTs were prepared as previously described 18 . Polydimethylsiloxane (PDMS; Sylgard 184 from 50 Corning) cantilever devices were molded from SU-8 masters, with embedded 1 µM fluorescent microbeads (carboxylate fluospheres; ThermoFisher). PDMS tissue gauge substrates were treated with 1 0.2% pluronic F127 (Sigma) for 30 minutes to reduce cell-extracellular matrix interactions. ICMs were 2 disassociated using trypsin digestion and mixed with stromal cells (human cardiac fibroblasts; single lot 3 obtained from Lonza), which were pre-treated with 10 µg/ml Mitomycin C (Sigma) to prevent cell 4 proliferation. The number of stromal cells was 7% of the total cell population, which is the quantity 5 necessary for tissue compaction. A suspension of 1.3e 6 cells within reconstitution mixture containing 2.25 6 mg/ml collagen I (BD Biosciences) and 0.5 mg/ml human fibrinogen (Sigma) was added to the substrate. 7 We measured CMT function at day seven to allow for tissue compaction and stability of force generation. 8 For quantifying tissue forces, fluorescence images were taken at 25 Hz with an Andor Dragonfly 9 microscope (Andor iXon 888 EMCCD camera with HC PL Fluotar 5X objective mounted on a DMI8 10 (Leica) microscope that was equipped with a fully-enclosed live-cell environmental chamber (Okolabs)).
11
All tissues were biphasic stimulated at 1 Hz with a C-Pace EP stimulator (IonOptix) and platinum wire 12 electrodes that were separated by 2 cm to the sides of the tissues tested. The displacement of fluorescent 13 microbeads was tracked using the ParticleTracker plug-in in ImageJ (National Institutes of Health). For metabolic stress assays, iCMs were cultured at sub-confluence in 6-well plates coated with 10 fibronectin (10ug/ml; Corning) at a density of 100,000 cells/well. Prior to metabolic stress conditions, 11 cells were maintained in RPMI with B27 supplement. To induce nutrient stress, cells were maintained in 12 glucose-free DMEM media (ThermoFisher) with B27 supplement for up to 7 days. To quantify iCM 13 death, either LDH released from dead cells was analyzed from conditioned media using an LDH release 14 assay (ThermoFisher), or viable cells were counted using live-cell imaging and a viability stain 15 (MitoTracker Red). ICM conditioned media was analyzed in a 96-well plate with a Synergy plate reader 16 (BioTek) to quantify absorbance at 490 nm and 680 nm. For ADP/ATP ratios, 20,000 iCMs were plated 17 on fibronectin-coated (10ug/ml; Corning) 96-well plates and analyzed by a bioluminescent ADP/ATP 18 assay (Biovision). 20 For iCM RNA sequencing experiments, total RNA was isolated from day 30-35 iCMs using Trizol 21 (ThermoFisher). CDNA was constructed using Superscript III First-Strand synthesis (ThermoFisher). For 22 each sample, total RNA from biological triplicates by differentiation batch was collected and sequenced. 23 RNA sequencing libraries were generated using the TruSeq Stranded mRNA library preparation kit 24 (Illumina). RNA sequencing libraries were sequenced on a HiSeq 2500 v4 SBS platform 2x100bp reads 25 (Illumina). Sequences were aligned with STAR 44 to the hg38 human genome. For differential expression, 26 DESeq2 (Bioconductor) was used. Heatmap analysis and hierarchical clustering were performed using the 27 Morpheus tool (Broad Institute). For quantitative PCR analysis, iCM total RNA was isolated and 28 processed as above. Gene-specific PCR primers were identified from the literature or designed using 29 Primer3 (see table S2 for sequences) and transcripts were quantified using Fast SYBR Green (Applied 30 Biosystems) on an ViiA7 Real-Time PCR system (Applied Biosystems).
19
RNA sequencing, quantitative PCR and computational analyses
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AFM Modulus Quantification
32
To measure the elastic modulus of the PDMS used for tissue gauge production, indentation measurements 33 were performed using Atomic Force Microscopy (AFM) (Asylum Research MFP-3D, Santa Barbara, Ca). 34 Using a colloidal silica spherical probe (AppNano FORT SiO 2 -A), a 16x16 array of force-distance curves 35 was acquired evenly spaced across a 2x2µm area for each measurement. Before and after these force- 36 volume experiments, identical force-distance measurements on an incompressible surface were performed 37 with a steel disk to calibrate the system sensitivity and to determine the spring constant for the force-38 transducing cantilever (1.75 nN/nm of deflection, within the range of specifications for these commercial 39 probes). All 256 force-distance curves for each location studied were analyzed based on the Johnson-40 Kendall-Roberts model of elastic contact. Such JKR mechanics accommodate large adhesion energies 41 between an indenting probe and sample 45, 46 , both expected and observed for these studies with PDMS. 42 This incorporates the following experimental parameters: the indenter possesses a spherical tip geometry 43 with a radius of 2.5 µm; the probe modulus appropriate for the colloidal silica sphere is 68.0 GPa; and this 44 probe exhibits a Poisson ratio of 0.19. A Poisson ratio of .33 is conventionally assumed for the specimen. 45 For each of the samples, force-volume maps were completed at three representative locations. The 46 average elastic modulus from the resulting 768 individual indentations per specimen is reported. Author Contributions: 
